Literature DB >> 15818104

Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome.

George Nakos1, Eirini Kitsiouli, Eleana Hatzidaki, Vassilios Koulouras, Lhousseine Touqui, Marilena E Lekka.   

Abstract

OBJECTIVE: Phospholipases A2 (PLA2) comprise a family of enzymes probably implicated in the development of acute respiratory distress syndrome (ARDS). The aim was to investigate PLA2 activities and characteristics in bronchoalveolar lavage (BAL) fluid, BAL cells, and plasma from patients with ARDS by a fluorometric method.
DESIGN: Prospective, controlled study.
SETTING: Fourteen-bed polyvalent intensive care unit in a university hospital. PATIENTS: A total of 31 mechanically ventilated patients, 20 with and 11 without ARDS, were studied. INTERVENTION: BAL was performed by fiberoptic bronchoscopy in mechanically ventilated patients with a controlled mechanical ventilation mode. MEASUREMENTS: PLA2 and platelet-activating-factor acetylhydrolase were determined in BAL fluid, cells, and plasma. For the classification of PLA2-specific inhibitors, Western blot analysis and their biochemical characteristics were used.
RESULTS: In ARDS patients, increased PLA2 levels were detected in BAL fluid, BAL cells, and plasma compared with the control patients. PLA2 in BAL fluid was mainly type IIA secretory and cytosolic types. In plasma, type IIA secretory and cytosolic and a Ca-independent PLA2 were found. In BAL cells, a cytosolic form, probably a Ca-independent intracellular form, and a low activity of type IIA secretory PLA2 was also observed. Total PLA2 activity correlated inversely with Pao2/Fio2 ratio and positively with the mortality rate. Patients with direct ARDS exhibited higher PLA2 activity compared with patients with indirect ARDS. Platelet-activating-factor acetylhydrolase activity was higher in BAL fluid and plasma, but it was lower in BAL cells.
CONCLUSION: Ca-dependent, secretory, cytosolic, and Ca-independent forms of PLA2 and platelet-activating-factor acetylhydrolase could play important roles in the development or down-regulation of inflammation in ARDS, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15818104     DOI: 10.1097/01.ccm.0000158519.80090.74

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  43 in total

1.  Biochemical parameters of bronchoalveolar lavage fluid in fat embolism.

Authors:  Georgia Karagiorga; George Nakos; Eftychia Galiatsou; Marilena E Lekka
Journal:  Intensive Care Med       Date:  2005-12-02       Impact factor: 17.440

2.  Synthesis and activity of a novel diether phosphonoglycerol in phospholipase-resistant synthetic lipid:peptide lung surfactants().

Authors:  Adrian L Schwan; Suneel P Singh; Jason A Davy; Alan J Waring; Larry M Gordon; Frans J Walther; Zhengdong Wang; Robert H Notter
Journal:  Medchemcomm       Date:  2011-10-19       Impact factor: 3.597

Review 3.  Multiple roles of phospholipase A2 during lung infection and inflammation.

Authors:  Bryan P Hurley; Beth A McCormick
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

4.  Circulating markers of endothelial and alveolar epithelial dysfunction are associated with mortality in pediatric acute respiratory distress syndrome.

Authors:  Nadir Yehya; Neal J Thomas; Nuala J Meyer; Jason D Christie; Robert A Berg; Susan S Margulies
Journal:  Intensive Care Med       Date:  2016-04-21       Impact factor: 17.440

5.  Group V phospholipase A2 mediates barrier disruption of human pulmonary endothelial cells caused by LPS in vitro.

Authors:  Steven M Dudek; Nilda M Muñoz; Anjali Desai; Christopher M Osan; Angelo Y Meliton; Alan R Leff
Journal:  Am J Respir Cell Mol Biol       Date:  2010-05-06       Impact factor: 6.914

6.  Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates.

Authors:  Daniele De Luca; Angelo Minucci; Domenico Tripodi; Marco Piastra; Domenico Pietrini; Cecilia Zuppi; Giorgio Conti; Virgilio P Carnielli; Ettore Capoluongo
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

7.  Surfactant protein B inhibits secretory phospholipase A2 hydrolysis of surfactant phospholipids.

Authors:  R Duncan Hite; Bonnie L Grier; B Moseley Waite; Ruud A Veldhuizen; Fred Possmayer; Li-Juan Yao; Michael C Seeds
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-28       Impact factor: 5.464

8.  Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration.

Authors:  Daniele De Luca; Angelo Minucci; Enrico Zecca; Marco Piastra; Domenico Pietrini; Virgilio P Carnielli; Cecilia Zuppi; Ascanio Tridente; Giorgio Conti; Ettore D Capoluongo
Journal:  Intensive Care Med       Date:  2008-10-14       Impact factor: 17.440

9.  Inhaled activated protein C protects mice from ventilator-induced lung injury.

Authors:  Nikolaos A Maniatis; Eleftheria Letsiou; Stylianos E Orfanos; Matina Kardara; Ioanna Dimopoulou; Georgios Nakos; Marilena E Lekka; Charalambos Roussos; Apostolos Armaganidis; Anastasia Kotanidou
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097

Review 10.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.